This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

TK216

Oncternal Therapeutics, Inc.

Drug Names(s): TK-216, TK 216

Description: TK216 is a small molecule that inhibits the biological activity of ets-family transcription factor oncoproteins in a variety of tumor types, stopping cancer cell growth and tumor formation. In Ewing sarcoma, it is designed to target a single and well-characterized genetic mutation that causes the disease.

Deal Structure: Tokalas and Oncternal Therapeutics
In June 2016, Oncternal Therapeutics and Tokalas announced that the two companies have completed a merger to create a new clinical-stage oncology company with two pipeline products. The transaction was approved by both companies shareholders, and results in the combination of all assets, research and developments programs and operations under the name Oncternal Therapeutics.

As a combined company, Oncternal Therapeutics will hold exclusive worldwide development and commercialization rights to cirmtuzumab and TK216 with potential across a range of cancer indications.


TK216 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug